Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 65

1.

Sequential Treatment with Bevacizumab and Aflibercept for Metastatic Colorectal Cancer in Real-World Clinical Practice.

Buchler T, Kiss I, Hornova J, Fiala O, Wiesnerova M, Svoboda M, Silar J, Kopeckova K, Poprach A, Finek J, Petruzelka L, Melichar B.

Target Oncol. 2020 Feb 12. doi: 10.1007/s11523-020-00705-1. [Epub ahead of print]

PMID:
32052341
2.

Novel serum markers HSP60, CHI3L1, and IGFBP-2 in metastatic colorectal cancer.

Vocka M, Langer D, Fryba V, Petrtyl J, Hanus T, Kalousova M, Zima T, Petruzelka L.

Oncol Lett. 2019 Dec;18(6):6284-6292. doi: 10.3892/ol.2019.10925. Epub 2019 Sep 26.

3.

Beyond tissue biopsy: a diagnostic framework to address tumor heterogeneity in lung cancer.

Voigt W, Manegold C, Pilz L, Wu YL, Müllauer L, Pirker R, Filipits M, Niklinski J, Petruzelka L, Prosch H.

Curr Opin Oncol. 2020 Jan;32(1):68-77. doi: 10.1097/CCO.0000000000000598.

PMID:
31714259
4.

Serum levels of TIMP-1 and MMP-7 as potential biomarkers in patients with metastatic colorectal cancer.

Vočka M, Langer D, Fryba V, Petrtyl J, Hanus T, Kalousova M, Zima T, Petruzelka L.

Int J Biol Markers. 2019 Sep;34(3):292-301. doi: 10.1177/1724600819866202. Epub 2019 Sep 4.

PMID:
31578137
5.

Estrogen Receptor Status Oppositely Modifies Breast Cancer Prognosis in BRCA1/BRCA2 Mutation Carriers Versus Non-Carriers.

Vocka M, Zimovjanova M, Bielcikova Z, Tesarova P, Petruzelka L, Mateju M, Krizova L, Kotlas J, Soukupova J, Janatova M, Zemankova P, Kleiblova P, Novotny J, Konopasek B, Chodacka M, Brychta M, Sochor M, Smejkalova-Musilova D, Cmejlova V, Kozevnikovova R, Miskarova L, Argalacsova S, Stolarova L, Lhotova K, Borecka M, Kleibl Z.

Cancers (Basel). 2019 May 28;11(6). pii: E738. doi: 10.3390/cancers11060738.

6.

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.

Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, Kubota K, Lubiniecki GM, Zhang J, Kush D, Lopes G; KEYNOTE-042 Investigators.

Lancet. 2019 May 4;393(10183):1819-1830. doi: 10.1016/S0140-6736(18)32409-7. Epub 2019 Apr 4.

PMID:
30955977
7.

Sequential therapy with bevacizumab and EGFR inhibitors for metastatic colorectal carcinoma: a national registry-based analysis.

Buchler T, Chloupkova R, Poprach A, Fiala O, Kiss I, Kopeckova K, Dusek L, Veskrnova V, Slavicek L, Kohoutek M, Finek J, Svoboda M, Petruzelka L, Melichar B.

Cancer Manag Res. 2018 Dec 28;11:359-368. doi: 10.2147/CMAR.S183093. eCollection 2019.

8.

Safe decontamination of cytostatics from the nitrogen mustards family. Part one: cyclophosphamide and ifosfamide.

Štenglová Netíková IR, Petruželka L, Šťastný M, Štengl V.

Int J Nanomedicine. 2018 Nov 26;13:7971-7985. doi: 10.2147/IJN.S159328. eCollection 2018.

9.

Use of Trastuzumab for Neoadjuvant Therapy of HER2+ Breast Cancer - 5-Years of Experience in a Single Clinic.

Zuazana B, Luboš P, Renata C.

Klin Onkol. Spring 2018;31(3):191-199. doi: 10.14735/amko2018191.

PMID:
30441972
10.

Impact of Delayed Addition of Anti-EGFR Monoclonal Antibodies on the Outcome of First-Line Therapy in Metastatic Colorectal Cancer Patients: a Retrospective Registry-Based Analysis.

Fiala O, Veskrnova V, Chloupkova R, Poprach A, Kiss I, Kopeckova K, Dusek L, Slavicek L, Kohoutek M, Finek J, Svoboda M, Petruzelka L, Boubliková L, Dvorak J, Melichar B, Buchler T.

Target Oncol. 2018 Dec;13(6):735-743. doi: 10.1007/s11523-018-0597-7.

PMID:
30353488
11.

Immunological examination of peripheral blood in patients with colorectal cancer compared to healthy controls.

Spacek J, Vocka M, Netikova I, Skalova H, Dundr P, Konopasek B, Zavadova E, Lubos P.

Immunol Invest. 2018 Oct;47(7):643-653. doi: 10.1080/08820139.2018.1480030. Epub 2018 Jun 20.

PMID:
29924680
12.

International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study.

Pagès F, Mlecnik B, Marliot F, Bindea G, Ou FS, Bifulco C, Lugli A, Zlobec I, Rau TT, Berger MD, Nagtegaal ID, Vink-Börger E, Hartmann A, Geppert C, Kolwelter J, Merkel S, Grützmann R, Van den Eynde M, Jouret-Mourin A, Kartheuser A, Léonard D, Remue C, Wang JY, Bavi P, Roehrl MHA, Ohashi PS, Nguyen LT, Han S, MacGregor HL, Hafezi-Bakhtiari S, Wouters BG, Masucci GV, Andersson EK, Zavadova E, Vocka M, Spacek J, Petruzelka L, Konopasek B, Dundr P, Skalova H, Nemejcova K, Botti G, Tatangelo F, Delrio P, Ciliberto G, Maio M, Laghi L, Grizzi F, Fredriksen T, Buttard B, Angelova M, Vasaturo A, Maby P, Church SE, Angell HK, Lafontaine L, Bruni D, El Sissy C, Haicheur N, Kirilovsky A, Berger A, Lagorce C, Meyers JP, Paustian C, Feng Z, Ballesteros-Merino C, Dijkstra J, van de Water C, van Lent-van Vliet S, Knijn N, Mușină AM, Scripcariu DV, Popivanova B, Xu M, Fujita T, Hazama S, Suzuki N, Nagano H, Okuno K, Torigoe T, Sato N, Furuhata T, Takemasa I, Itoh K, Patel PS, Vora HH, Shah B, Patel JB, Rajvik KN, Pandya SJ, Shukla SN, Wang Y, Zhang G, Kawakami Y, Marincola FM, Ascierto PA, Sargent DJ, Fox BA, Galon J.

Lancet. 2018 May 26;391(10135):2128-2139. doi: 10.1016/S0140-6736(18)30789-X. Epub 2018 May 10.

PMID:
29754777
13.

Anthracycline antibiotics derivate mitoxantrone-Destructive sorption and photocatalytic degradation.

Štenglová-Netíková IR, Petruželka L, Šťastný M, Štengl V.

PLoS One. 2018 Mar 13;13(3):e0193116. doi: 10.1371/journal.pone.0193116. eCollection 2018.

14.

Growth/differentiation factor 15 (GDF-15) as new potential serum marker in patients with metastatic colorectal cancer.

Vocka M, Langer D, Fryba V, Petrtyl J, Hanus T, Kalousova M, Zima T, Petruzelka L.

Cancer Biomark. 2018;21(4):869-874. doi: 10.3233/CBM-170792.

PMID:
29400662
15.

Molecular pathological predictive diagnostics in a patient with non-small cell lung cancer treated with crizotinib therapy: A case report.

Stanek L, Springer D, Konopasek B, Vocka M, Tesarova P, Syrucek M, Petruzelka L, Vicha A, Musil Z.

Oncol Lett. 2017 Dec;14(6):7545-7548. doi: 10.3892/ol.2017.7167. Epub 2017 Oct 11.

16.

5-fluorouracil Toxicity Mechanism Determination in Human Keratinocytes: in vitro Study on HaCaT Cell Line.

Hartinger J, Veselý P, Šíma M, Netíková I, Matoušková E, Petruželka L.

Prague Med Rep. 2017;118(4):128-138. doi: 10.14712/23362936.2017.14.

17.

Molecular characterization and heterogeneity of circulating tumor cells in breast cancer.

Jakabova A, Bielcikova Z, Pospisilova E, Matkowski R, Szynglarewicz B, Staszek-Szewczyk U, Zemanova M, Petruzelka L, Eliasova P, Kolostova K, Bobek V.

Breast Cancer Res Treat. 2017 Dec;166(3):695-700. doi: 10.1007/s10549-017-4452-9. Epub 2017 Aug 16.

18.

Migrastatics-Anti-metastatic and Anti-invasion Drugs: Promises and Challenges.

Gandalovičová A, Rosel D, Fernandes M, Veselý P, Heneberg P, Čermák V, Petruželka L, Kumar S, Sanz-Moreno V, Brábek J.

Trends Cancer. 2017 Jun;3(6):391-406. doi: 10.1016/j.trecan.2017.04.008. Review.

19.

MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study.

Hickish T, Andre T, Wyrwicz L, Saunders M, Sarosiek T, Kocsis J, Nemecek R, Rogowski W, Lesniewski-Kmak K, Petruzelka L, Apte RN, Mohanty P, Stecher M, Simard J, de Gramont A.

Lancet Oncol. 2017 Feb;18(2):192-201. doi: 10.1016/S1470-2045(17)30006-2. Epub 2017 Jan 14.

PMID:
28094194
20.

Plasma Phosphatidylcholines Fatty Acids in Men with Squamous Cell Esophageal Cancer: Chemoradiotherapy Improves Abnormal Profile.

Zemanova M, Vecka M, Petruželka L, Staňková B, Žák A, Zeman M.

Med Sci Monit. 2016 Oct 30;22:4092-4099.

Supplemental Content

Loading ...
Support Center